Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.42 |
| ▸ | CCND1 | P24385 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11535686 | 0.86 | SMN1; SMN2 (0.46) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL23598170 | 0.84 | CSNK1E (0.44) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL13677547 | 0.82 | LMNA (0.51) | DYRK1ABRD4SMN1; SMN2LMNANPC1 | |
| SCHEMBL12853410 | 0.81 | FABP4 (0.48) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL29827557 | 0.81 | FABP4 (0.48) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL21122511 | 0.78 | CSNK1E (0.40) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL17586641 | 0.78 | CDK1 (0.56) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL12349865 | 0.77 | SMN1; SMN2 (0.45) | CSNK1ECLK1CLK2CLK3GSK3B | |
| SCHEMBL19836570 | 0.77 | KMT2A (0.47) | BRD4SMN1; SMN2LMNATSHRHSD17B10 | |
| SCHEMBL27120383 | 0.76 | CDK9 (0.49) | CLK1DYRK1ADYRK2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
| WO-2020151742-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-07-30 | — | — | WO | disclosed |
| US-10550103-B2 | Dual inhibitors of PARP1 and CDK | Accutar Biotechnology (US) | 2020-02-04 | — | — | US | disclosed |
| US-10519136-B2 | Dual inhibitors of PARP1 and CDK | Accutar Biotechnology (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190202806-A1 | DUAL INHIBITORS OF PARP1 AND CDK | ACCUTAR BIOTECHNOLOGY INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202807-A1 | DUAL INHIBITORS OF PARP1 AND CDK | Accutar Biotechnology | 2019-07-04 | — | — | US | disclosed |
| EP-3492462-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| WO-2018019204-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202806-A1 | DUAL INHIBITORS OF PARP1 AND CDK | PARP1, PARP11, PARP12 | CSNK1E 358/4885CLK1 239/4885CLK2 236/4885 |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | CDK3, CDK4, CDK1 | CSNK1E 69/4885CLK1 463/4885CLK2 369/4885 |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | LCK, WEE1, JAK1 | CSNK1E 99/4885CLK1 1644/4885CLK2 1324/4885 |
| US-10519136-B2 | Dual inhibitors of PARP1 and CDK | PARP1, PARP11, PARP12 | CSNK1E 358/4885CLK1 239/4885CLK2 236/4885 |
| US-10550103-B2 | Dual inhibitors of PARP1 and CDK | PARP1, PARP11, PARP12 | CSNK1E 358/4885CLK1 239/4885CLK2 236/4885 |
| US-20190202807-A1 | DUAL INHIBITORS OF PARP1 AND CDK | PARP1, PARP11, PARP12 | CSNK1E 358/4885CLK1 239/4885CLK2 236/4885 |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | LCK, WEE1, JAK1 | CSNK1E 99/4885CLK1 1644/4885CLK2 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.